<?xml version="1.0" encoding="UTF-8"?>
<p>Papanicolaou et al. used dose-blinded maribavir 400, 800, or 1200 mg twice-daily for up to 24 weeks to treat hematopoietic-cell or SOT recipients (â‰¥12 years old) with refractory or resistant CMV infections in a phase II and double-blind clinical trial [
 <xref rid="B47-viruses-12-00021" ref-type="bibr">47</xref>]. The result revealed that it was active to against refractory or resistant CMV infections using maribavir more than 400 mg twice daily in transplant recipients and no new safety signals were identified in this trial [
 <xref rid="B47-viruses-12-00021" ref-type="bibr">47</xref>].
</p>
